94 results about "Interventricular septum" patented technology

The present disclosure relates to a RF ablation catheter for septal reduction therapy having a cooling effect, and more particularly, to a RF ablation catheter for septal reduction therapy that is for performing RF ablation, in which RF energy is applied to an interventricular septum, for septal reduction therapy such as therapy for hypertrophic cardiomyopathy, which is a disease in which an interventricular septum of the left ventricle of the heart of the animal or human body thickens, therapy that requires reduction of an interventricular septum, or therapy for ventricular tachycardia. Also, the present disclosure relates to a RF ablation catheter for septal reduction therapy having a cooling effect that is for preventing carbonization of a tissue of the body (interventricular septum) around an electrode.An exemplary embodiment of the present disclosure provides a RF catheter for septal reduction therapy, the RF catheter including: an intra-septal part in which a tapered tip which becomes thinner toward an end thereof is formed at an end of a distal part and one or more electrodes are formed at positions on an outer circumferential surface that are adjacent to the tip; and a body part which is made of a soft material and has a guidewire lumen which passes through the intra-septal part from an inlet formed at the center of the end of the tip and has an outlet formed in a side surface, a coolant inlet lumen which is connected from a proximal part to an inner portion of the intra-septal part to allow a coolant to be injected from the outside and which has an open end, and a coolant outlet lumen which communicates with the coolant inlet lumen and has an exit formed in a side surface, wherein the guidewire lumen and the coolant inlet lumen do not communicate with each other and are partitioned from each other.

The present invention relates to a radiofrequency electrode ablation catheter for ventricular septal therapy with a cooling function, which is used for performing radiofrequency electrode ablation and has a cooling function for preventing carbonization of body (ventricular septum) tissue around the electrode, wherein radiofrequency energy is applied to the ventricular septum during radiofrequency electrode ablation to perform ventricular septal therapy (e.g., therapy for hypertrophic cardiomyopathy, a disease in which the left ventricular septum of the heart of an animal or human body becomes thickened, therapy requiring reduction of the ventricular septum, or ventricular tachycardia, etc.). The radiofrequency catheter for ventricular septal therapy according to a preferred embodiment of the present invention includes a septal insertion portion and a body portion.

The invention relates to a simulation-based target removal area determination method and device. The method comprises the following steps: acquiring a heart simulation model and corresponding blood flow field information; according to the left heart lumen model and the blood flow field information, determining a first target area in the ventricular septum model; stress calculation is carried out according to the ventricular septum model, and a second target area in the ventricular septum model is determined; determining an initial target area according to the first target area and the second target area; according to the ventricular septum model, determining the thickness range of the initial target area at the end of contraction; determining a target cutting thickness according to a preset basic thickness and a thickness range; according to the heart simulation model, the initial target area, the target resection thickness and the blood flow field information, a first target resection area is determined. By adopting the method, the cardiac muscle tissue area needing to be cut off can be accurately determined.

The invention provides an integrated structure double-ventricle independent auxiliary device and an implantation method. The device comprises double inlet paths and double outlet paths which are connected, the double inlet paths are of a double-cavity structure and comprise an inner cavity and an outer cavity, the double inlet paths are implanted through the apex of the left ventricle, the inner cavity is inserted into the apex of the funnel of the right ventricle through the corresponding ventricular septum at the opening of the left ventricle, and the outer cavity is reserved in the left ventricle; and the double outlets are respectively connected with the aorta and the pulmonary artery through the artificial blood vessel by a circulation driving device. Left and right artificial ventricle admission passages are located in the heart, and channel distortion, large blood damage and proneness to thrombus caused by long admission passages are avoided; unsmooth drainage of a right chamber or right ventricle admission passage can be avoided; the right chamber is not damaged; the whole device is small in size and convenient to implant.

A system for percutaneous ventriculoplasty. Anchors can be placed in the ventricular septum and the ventricular wall. Sutures tethered to the anchors can be tensioned to reduce the size of a dilated left ventricle. Multiple anchors can be positioned in the ventricular wall and the sutures can be independently tensioned to allow tailored treatment of the dilated ventricle.

The invention discloses a TSDNet-based ventricular septal defect positioning system and method. The system comprises an acquisition module, a construction module and a positioning module, the acquisition module is used for acquiring ultrasonic electrocardiogram videos under a plurality of standard views and taking the ultrasonic electrocardiogram videos with labels as a sample data set; the construction module is used for constructing a ventricular septal defect positioning model based on the data set, and the ventricular septal defect positioning model adopts a TSDNet network architecture and comprises a UniFormer model for judging whether an echocardiogram video is negative or positive and an optimized YOLOv5 model for detecting a ventricular septal defect focus area; and the positioning module is used for completing ventricular septal defect positioning by using the ventricular septal defect positioning model. The invention provides a space-time decoupling network, which performs efficient analysis by separating time sequence and space features in an echocardiogram video, and realizes video-level classification of ventricular septal defect and accurate positioning of a shunting area.

The invention discloses a heart occluder fatigue test device, which comprises a liquid supply unit and a clamping unit, and is characterized in that the liquid supply unit comprises a liquid storage mechanism capable of accommodating a test solution, and the liquid storage mechanism can be connected with a power mechanism; the clamping unit comprises a first connector and a second connector. The heart occluder is arranged between the first connector and the second connector, the heart occluder to be tested is fixed after the first connector and the second connector are connected, a test solution is injected into the liquid storage mechanism, the temperature control element can control the temperature of the test solution so that the test condition can be met, the first connector is communicated with the liquid storage mechanism, and the second connector is communicated with the liquid storage mechanism. A test solution is conveyed into the liquid storage mechanism through the power mechanism, the pressure on the two sides of the heart occluder is adjusted, the elastic state that the heart occluder makes direct contact with soft tissue at the ventricular septal defect is simulated, and the liquid exudation condition at the heart occluder and the damage condition of the heart occluder after test are observed. Therefore, the fatigue performance data of the heart occluder is obtained.

An implantable device can be configured to occlude an opening in a septum of a heart, such as a perimembranous ventricular septal defect. The device can comprise an expandable member expandable from a first state to a second state upon contact with a fluid. The implantable device in the second state can be configured to occlude the opening in the septum, thereby preventing blood from leaking through the opening and across the septum. The implantable device can be substantially or completely devoid of metal, resulting in a reduced likelihood that the implantable device affects the function of heart valves near the opening of the septum or leads to tissue erosion.

A biostimulator and a biostimulator system for septal pacing, is described. The biostimulator includes an articulation to allow an electrode axis of a pacing electrode to be directed differently than a housing axis of a housing. The housing contains electrical circuitry that is electrically connected to the pacing electrode. The differently directed axes allow the pacing electrode to affix to target tissue of an interventricular septal wall of a heart when the housing of the biostimulator is located near an apex of the heart. The articulation can include a flexible portion of an extension, a hinge, or a tether. Other embodiments are also described and claimed.

An apparatus includes a flexible elongate member configured to be advanced through a blood vessel and positioned inside the heart of a patient. The apparatus also includes at least one expandable member coupled to a distal portion of the flexible elongate member, and a plurality of electrodes coupled to the at least one expandable member. When the at least one expandable member is in an expanded configuration, the at least one expandable member is configured to bring the plurality of electrodes into contact with an interventricular septum of the hear. When the plurality of electrodes is in contact with the interventricular septum, the plurality of electrodes is configured to deliver electrical energy to the interventricular septum to reduce a volume of the interventricular septum.

This invention discloses a method for preparing a simulated heart model and the simulated heart model itself. The method for preparing the simulated heart model includes: dividing a digital heart model into two parts along its coronal plane; preparing corresponding molding molds according to the structural characteristics of the two parts, each molding mold including an outer molding mold and an inner cavity molding mold; applying silicone to the molding surfaces of the outer molding mold and the inner cavity molding mold to form the endocardium and epicardium; applying silicone to the portion of the inner cavity molding mold used for molding the valve to form the valve; assembling the outer molding mold and the inner cavity molding mold to form a cavity; sequentially injecting silicone of corresponding hardness into the regions of the cavity used for molding the atrial myocardium, interatrial septal myocardium, ventricular myocardium, and interventricular septal myocardium to form heart model halves; and bonding the heart model halves corresponding to the two molding molds together to obtain the simulated heart model.

A mechanical device for voluntarily creating a remedial atrial septal defect, a sheathed vascular dilator that includes the mechanical device, and methods of voluntarily creating a remedial atrial septal defect in an atrial septum using the mechanical device. The mechanical device includes leading and trailing flanges separated by a circular gap with a circular sharp on the leading flange projecting towards the circular gap.

The utility model discloses a first-aid device used for relieving SAM symptoms, which comprises a lead puncture sheath tube, a first-aid device is arranged in the lead puncture sheath tube, the first-aid device comprises a hollow sheath tube with an inclined top end, a channel is arranged on the tube wall of the hollow sheath tube, a jacking component is mounted in the hollow sheath tube, and a propelling component is arranged at the bottom end of the hollow sheath tube. The bottom end of the jacking assembly is connected with the top end of the pushing assembly, a main supporting strip and an auxiliary supporting strip of the jacking assembly can open and close the elastic umbrella cover, the pushing assembly is used for pushing the jacking assembly forwards to enable the jacking assembly to stretch out of the top end of the hollow sheathing canal to open the elastic umbrella cover, an anti-falling plate is further arranged at the bottom end of the hollow sheathing canal, and the pushing assembly is inserted into the anti-falling plate. The device is reasonable in structure and easy and convenient to operate, is applied to the first-aid operation of the SAM symptom patient, and can be used for rapidly jacking up the mitral valve anterior lobe to be separated from the ventricular septum, widening the left ventricular outflow tract and win time for the subsequent treatment of the patient.

The utility model relates to the technical field of ventricular septum perforation plugging devices, and discloses a novel ventricular septum perforation plugging device which comprises a fixing column and a first disc-shaped net arranged on the outer side of the fixing column, a connecting waist part is further arranged on the outer side of the fixing column, and the connecting waist part is connected with the first disc-shaped net. A second disc-shaped net is arranged on the side, away from the first disc-shaped net, of the connecting waist part, an end is arranged on one side of the second disc-shaped net, and before use, a small screw at the front end of a transmission steel cable is used for being connected with the end, so that the whole compressed plugging device can be transmitted to a heart defect part through a pipeline; the first disc-shaped net and the second disc-shaped net are used for blocking, the defect part can be blocked, the biological membrane can make contact with the heart defect part, the sealing performance is further improved, meanwhile, the polyurethane coating has certain flexibility, friction between the polyurethane coating and the heart defect part is effectively reduced, and the service life of the heart defect part is prolonged. The heparin coating can reduce the risk of thrombus formation, so that the use risk is reduced.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

This invention discloses a method for predicting sudden cardiac death based on forensic autopsy data using machine learning and its forensic applications, belonging to the fields of machine learning, statistics, and forensic identification. This invention provides a method for screening independent predictors of forensic diagnosis of sudden cardiac death using LASSO regression and logistic regression. Using 10-fold cross-validation, the method selects the minimum lambda(λ) to identify 14 risk factors. Logistic regression ultimately identifies 9 independent predictors, including age, heart weight, left ventricular wall thickness, right ventricular wall thickness, interventricular septum thickness, aortic valve circumference, mitral valve circumference, liver weight, and left kidney weight. A nomogram and a web-based calculator are constructed for predicting sudden cardiac death in forensic practice, thereby determining sudden cardiac death using objective indicators. This method has not been reported worldwide.

The invention discloses a first-aid device for relieving SAM symptoms, which comprises a guide puncture sheathing canal, a first-aid device is arranged in the guide puncture sheathing canal, the first-aid device comprises a hollow sheathing canal of which the top end is an inclined plane, a channel is formed in the wall of the hollow sheathing canal, a jacking component is mounted in the hollow sheathing canal, and a propelling component is arranged at the bottom end of the hollow sheathing canal. The bottom end of the jacking assembly is connected with the top end of the pushing assembly, a main supporting strip and an auxiliary supporting strip of the jacking assembly can open and close the elastic umbrella cover, the pushing assembly is used for pushing the jacking assembly forwards to enable the jacking assembly to stretch out of the top end of the hollow sheathing canal to open the elastic umbrella cover, an anti-falling plate is further arranged at the bottom end of the hollow sheathing canal, and the pushing assembly is inserted into the anti-falling plate. The device is reasonable in structure and easy and convenient to operate, is applied to the first-aid operation of the SAM symptom patient, and can be used for rapidly jacking up the mitral valve anterior lobe to be separated from the ventricular septum, widening the left ventricular outflow tract and win time for the subsequent treatment of the patient.

The invention relates to an in-vitro left heart near physiological environment simulation system and method based on an isolated heart, and relates to the technical field of medical instruments. The system comprises a simulation assembly and an external circulation unit. A shell of the simulation assembly is transparent and used for containing the isolated heart, a top cover is provided with an inflow channel, an outflow channel and an observation window, and a reciprocating pump changes a containing cavity through an isolating membrane to hydraulically drive the heart. The external circulation unit is provided with a resistance valve, a compliance assembly and the like. The method comprises the steps of treating the isolated heart, connecting pipelines, assembling parts, adjusting liquid flow and pressure and the like. The left heart dynamic near-physiological simulation of the isolated heart can be realized, the valve movement can be conveniently observed, and the heart movement can be observed from different angles. More importantly, a near-physiological in-vitro testing environment can be provided for cardiovascular implantation and intervention medical instruments (such as an intervention type mitral valve, a mitral valve forming ring and a ventricular septum plugging device), and a way is provided for researching the influence of the near-physiological in-vitro testing environment on valve movement and left heart movement.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating ventricular remodeling and a preparation method thereof. The traditional Chinese medicine composition for preventing and treating ventricular remodeling is prepared from the following raw materials: 25 to 35 parts of radix astragali seu hedysari, 10 to 15 parts of cassia twig, 10 to 15 parts of peach kernel, 12 to 18 parts of flos carthami and 7 to 11 parts of semen lepidii. According to the traditional Chinese medicine composition, the left ventricular posterior wall thickness, the ventricular septum thickness and the left ventricular end diastolic inner diameter are obviously increased, the left ventricular end systolic inner diameter, the left ventricular mass index and the right ventricular mass index are obviously reduced, and it is prompted that the traditional Chinese medicine composition can inhibit ventricular remodeling of rats suffering from ischemic cardiomyopathy.

The present invention discloses a cardiac ablation needle, and the electrode needle body is disposed through the outer sleeve. The distal end of the electrode needle body extends out of the outer sleeve. A cavity is formed in the middle of the electrode needle body, and a discharge hole is formed at the distal end of the electrode needle body. The other end of the discharge hole communicates with the cavity, and hydrogen peroxide is injected inside the cavity. It solves the problem in the prior art that for patients with a relatively large size of ventricular septal hypertrophy, the cardiac ablation needle cannot meet the requirement of accurately adjusting the position of the ablation needle after one ablation and fulfilling the function of multiple ablations. This cardiac ablation needle forms a cavity inside the electrode needle body. The hydrogen peroxide in the cavity plays a role in controlling the temperature of the electrode needle body. Secondly, through the oxidation-reduction reaction of hydrogen peroxide, a small amount of the generated oxygen enters the ventricular septal position, meeting the purpose of ultrasonic imaging, accurately imaging the position of the electrode needle body, facilitating the precise adjustment of the ablation position of the ablation needle, fulfilling multi-position ablation with one puncture, and improving the treatment effect.

A system for percutaneous ventriculoplasty. Anchors can be placed in the ventricular septum and the ventricular wall. Sutures tethered to the anchors can be tensioned to reduce the size of a dilated left ventricle. Multiple anchors can be positioned in the ventricular wall and the sutures can be independently tensioned to allow tailored treatment of the dilated ventricle.

Mitral regurgitation can be reduced by creating one passageway between the right atrium and left ventricle in a portion of the tricuspid annulus just above the ventricular septum and another passageway through the outer wall of the left ventricle near at least one of the left ventricular papillary muscles. A support rod is positioned in the right atrium in contact with the septal portion of the tricuspid annulus, and a support plate is positioned adjacent to the second passageway and against the outer wall of the left ventricle. The support plate is pulled toward the support rod using a tether that extends between the first support plate and the support rod, passes through both passageways, and is under tension. The tension in the tether moves the root of the tendon closer to the mitral valve, which reduces mitral regurgitation.

This invention relates to a biodegradable cardiac occluder for bilateral ventricular septal defect closure, comprising a first disc-shaped mesh, a second disc-shaped mesh, a tubular portion, and a rivetless flat-face connector. The tubular portion connects the first and second disc-shaped meshes. The rivetless flat-face connector includes a delivery disc and threaded holes. The delivery disc has mesh fixing holes for connecting the first disc-shaped mesh and the delivery disc. A steel cable can be connected to the occluder via the threads and threaded holes. This invention uses a small disc to replace rivets, achieving both re-delivery and the goal of reducing thrombosis incidence through rivetless design. The rivetless flat-face connector can be biodegradable or non-biodegradable. During processing, it is woven into the mesh body, making it convenient, safe, and quick.

An implantable assembly suitable for remodeling a chamber of a heart in a patient is disclosed. The assembly is implanted with a tool having a tool proximal portion and a distal portion. The assembly includes a mobile anchor including an abutment portion adapted to abut against a wall of the chamber of the heart and a tether portion rotatably coupled to the abutment portion. Each of the abutment portion and the tether portion are configured to be independently coupled from the tool. The assembly further includes an interventricular septum anchor for coupling to a septum of the heart and a tether having a working portion extending between the mobile anchor and the septum anchor having a first length and a tether proximal portion having a second length. The abutment portion is releasably locked to the tether portion and is configured such that a preselected torque applied to the tether portion of the mobile anchor unlocks and causes relative rotation of the tether portion relative to the abutment portion.

A detachable leadless pacemaker system for cardiac conduction bundle pacing is disclosed. The system includes a detachable leadless pacemaker and a passive leadless pacemaker. A hook-shape side electrode is inserted into a ventricular septum for cardiac conduction bundle pacing. The detachable leadless pacemaker may be arranged in a ventricle, and the passive leadless pacemaker may be arranged in an atrium, so as to realize dual-chamber pacing both in the ventricle and in the atrium. The detachable leadless pacemaker is coupled with the passive leadless pacemaker by an anti-tension reinforced wire, which is used for pulling back the detachable leadless pacemaker to a new position.

Systems, apparatuses, and methods disclosed herein are provided for medical treatment, including transcatheter medical treatments and / or for treatment of dilated hearts (e.g., dilated left ventricle) or functional mitral valve regurgitation within a human heart. The systems, apparatuses, and methods disclosed herein may include applying one or more heart splints to the patient's heart to apply pressure to the heart to reshape the heart. Anchors disclosed herein may be utilized in plugs for treating openings in a septum between two chambers of a heart, e.g., ventricular septal defects (VSD), atrial septal defects (ASD), and patent foramen ovale (PFO). In addition, the anchors disclosed herein may be utilized to reshape an annulus of a patient's heart valve, including a tricuspid valve of a patient's heart. The anchors disclosed herein may also be utilized to reposition a heart valve leaflet to reduce heart valve leaflet prolapse.

The present invention proposes a hypertrophic obstructive cardiomyopathy ablation device, which includes an adjustable bend sheath assembly, a mapping catheter, an ablation needle assembly, and an ultrasound assembly. The mapping catheter is inserted into the adjustable bend sheath assembly and can be moved along the axial direction of the adjustable bend sheath assembly to the distal end of the adjustable bend sheath assembly to exit. The mapping catheter is used to map the heart, and the ablation needle assembly is used to chemically ablate the hypertrophic portion of the ventricular septum of the right ventricle. The ultrasound assembly can be moved to the distal end of the adjustable bend sheath assembly to exit, and the ultrasound assembly is used to monitor the position of the ablation needle assembly. The hypertrophic obstructive cardiomyopathy ablation device integrates the ultrasound assembly, the ablation needle assembly, and the mapping catheter. Under the real-time image guidance of the ultrasound assembly, the ablation needle assembly is controlled to chemically ablate the hypertrophic portion of the myocardium, ensuring the accuracy of the ablation position and the ablation depth. Under the premise of ablation safety, alcohol ablation is given to cause myocardial necrosis in the deep layer of the ventricular septum to relieve the obstruction.

The invention discloses a direction-adjustable bending radiofrequency ablation electrode needle which comprises an ablation needle handle, a coaxial sheath, a steering electrode needle, an electrode wire, an outflow tube, an inflow tube and a negative electrode patch. The steering electrode needle is arranged in an inner cavity of the ablation needle handle and the coaxial sheath, the steering electrode needle made of shape memory alloy and the coaxial sheath are matched in a push-pull mode to synchronously adjust and control the length and the angle of the electrode needle, the needle point of the electrode needle is coated with the conductive nanometer coating, protein, tissue and the like are prevented from being adhered to the needle point, and carbonization is reduced. The direction of the ablation electrode needle and the length of the working end can be adjusted and controlled, a safer, more effective and more stable operation ablation treatment mode is achieved through the conductive ceramic coating on the needle tip part, the electrode needle can be suitable for Liwen operation type treatment of complex hypertrophic cardiomyopathy ventricular septal parting, and the safety, effectiveness and operability of the Liwen operation type operation process can be improved.

This application provides an ultrasound cardiac dynamic monitoring system and method, relating to the field of ultrasound cardiac function dynamic monitoring technology. The system includes: a patch-type ultrasound probe, a hydrogel patch, a wearable hardware module, and a cardiac function analysis module. The cardiac function analysis module is configured to: receive the ultrasound image; determine a target sampling line in the ultrasound image based on a reinforcement learning model; control the wearable hardware module to acquire M-mode images along the target sampling line; input the M-mode images into a deep learning model to output the key point positions of the left ventricular septum and the left ventricular posterior wall at end-diastole and end-systole based on the deep learning model; calculate the left ventricular ejection fraction (LVEF) based on the LVEF and the key point positions; the LVEF represents the dynamic monitoring and detection results of cardiac function. This system can improve the effectiveness and accuracy of dynamic cardiac monitoring.